Therapeutic development for human diseases continues to face obstacles, particularly in translating targets or compounds identified by in vitro screening campaigns to valid targets or efficacious and safe compounds once tested in humans. Here we discuss strategies that leverage induced pluripotent stem cells (iPSCs) to increase the relevance of human cell models for these in vitro approaches. We review current advances in genome engineering to pivot from challenges with delivery, identification and selection and subsequent clonal outgrowth by leveraging tools to consistently and reliably generate knock-out and knock-in models for use in target or compound identification. Specifically, we demonstrate this approach with iPSCs to build isogenic disease models, which can be further differentiated to various cell types of interest such as cardiomyocytes and dopaminergic neurons to model disease and are more directly related to a disease area than commonly used immortalized cell lines. We expect strategies combining genome engineering and stem cells to provide platforms for more robust disease models that will provide more predictable translation of in vitro to in vivo results.
Cell Biology
Biotechnology
Molecular Biology
Genetics
Cell Culture
Cancer Research
Biomarkers
Biochemistry
Gene Expression
Immunology
Genomics
Stem Cell Technologies
Dna
Gene Sequencing
Clinical Research
North America43%
Europe28%
Asia14%
South America8%
Africa8%
Website Visitors100%
Student20%
Research Scientist17%
Scientist15%
Educator/Faculty13%
Post Doc6%
Medical Doctor/Specialist5%
Facility/Department Manager4%
Medical Laboratory Technician4%
Executive3%
Lab Management3%
Biologist2%
Clinical Laboratory Scientist2%
Consultant2%
Engineer1%
Chemist1%
Veterinarian1%
Academic Institution19%
Research Institute8%
Biotech Company4%
Medical School3%
Clinical Laboratory3%
Government3%
Hospital2%
Ambulatory Care2%
Life Science Company2%
Medical Center1%
Dental Office1%
Non-Profit Organization1%
Independent Laboratories1%
Medical Device Company1%
Other3%